Related Experiment Video
Updated: May 12, 2026

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
Published on: August 25, 2014
Caffeine use in preterm neonates: national insights into Turkish NICU practices
Sezin Unal1, Serdar Beken2, Deniz Anuk Ince1
1Division of Neonatology, Department of Pediatrics, Baskent University Faculty of Medicine, Ankara, Türkiye.
Insights
Caffeine citrate use in premature infants varies significantly across neonatal intensive care units. This variability highlights the need for standardized national guidelines on prophylactic caffeine administration for preterm infants.
Area of Science:
- Neonatology
- Pharmacology
- Pediatrics
Background:
- Caffeine citrate is a key medication for preventing and treating apnea in premature infants.
- International guidelines exist for caffeine prophylaxis in preterm infants, but national guidelines may differ.
- Variability in current caffeine usage practices necessitates updated recommendations.
Purpose of the Study:
- To describe the current practices and variability in caffeine citrate usage among neonatal intensive care units in Turkey.
- To compare current practices with existing national and international guidelines.
Main Methods:
- An online survey was distributed to neonatologists who are members of the Turkish Neonatology Society.
- The survey collected data on prophylactic caffeine usage, including gestational age eligibility, timing, dosage, and duration of treatment.
- Responses from 74 neonatal intensive care units were analyzed.
Main Results:
- Prophylactic caffeine use varied by gestational age, with higher rates in earlier gestations (e.g., 98.6% for GA ≤27 6/7 weeks).
- Dosing strategies and adjustment protocols showed considerable variation among units.
- Significant intra-unit variations in caffeine administration were reported by over 30% of units with multiple physicians.
Conclusions:
- There are significant differences in caffeine citrate usage characteristics both between and within neonatal intensive care units.
- The observed variability underscores the urgent need for standardized national guidelines to ensure consistent and evidence-based care for preterm infants receiving caffeine prophylaxis.
Objective:
Caffeine is a proven medication used for the prevention and treatment of apnea in premature infants, offering both short- and long-term benefits. International guidelines provide a range of recommendations regarding the preterm population eligible for caffeine prophylaxis, including the timing, dosage, and duration of treatment. Our national guidelines, published prior to the most recent updates of the international guidelines, recommend the use of caffeine citrate starting from the first day after delivery for preterm infants with a gestational age of <28 weeks. For infants up to 32 weeks, if positive pressure ventilation is required, the decision should be made on an individual basis. This study aims to describe the variability in caffeine usage across neonatal intensive care units in our country.
Methods:
An online survey was sent to neonatologist who are members of the Turkish Neonatology Society to describe the variability in caffeine usage in neonatal intensive care units in our country.
Results:
We collected responses from 74 units. Prophylactic caffeine usage was observed as; GA ≤276/7: 98.6%, GA 280/7-286/7: 89.0%, GA 290/7-296/7: 75.3%, GA 300/7-316/7: 53.4%. 62.2% of units reported administering loading dose within the first two hours. The initial maintenance dose was 5 mg/kg in 64.8% of units, 10 mg/kg in 32.4% of units, and intermediate dose in 5.3% of units. 47.3% of units reported no routine dose adjustment. The postmenstrual age that caffeine treatment was stopped was found to be 34 (min-max; 32-36) weeks for infants without apnea and respiratory support, 36 (min-max; 34-52) weeks for infants without apnea but any respiratory support. The time to discharge after treatment cessation was found as; 1-4 days: 37.8%, 5-7 days: 68.9%. Among the 56 units with multiple responsible physicians, 32.1% reported intra-unit variations.
Conclusion:
The significant differences in caffeine usage characteristics between and within units highlight the need for clear recommendations provided by standardized guidelines.
Related Concept Videos
Drug Dosing: Infants and Children
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Pharmacokinetics in Pediatric Patients: Drug Distribution
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacokinetics in Pediatric Patients: Drug Excretion

